Wells Fargo Q3: AstraZeneca Rises to Top Holding, NVIDIA Stake Increased by Over 10%
nashnova research
Wells Fargo's Q3 13F shows total holdings at ~$640 billion. UK pharma giant AstraZeneca jumped from near-zero weight to the No. 1 position in a single quarter, while Nvidia saw a 10.5% stake increase — the bank's chips are shifting from pure tech to a pharma-plus-tech dual axis.
How did AstraZeneca go from nowhere to No. 1 in one quarter?
AstraZeneca ended the quarter at ~$26.41 billion in market value, 4.10% of the portfolio — up from just 0.05% last quarter. That 4.05-percentage-point single-quarter jump knocked Apple off the top spot.
This means → Wells Fargo executed an extremely concentrated build in Q3, large enough to vault a single name straight to the top.
In plain terms = last quarter they barely held any; this quarter it became their biggest bet — not gradual accumulation, but a single heavy move.
Is the tech allocation growing or shrinking?
Nvidia rose from ~58.86 million shares to ~65.05 million, a 10.51% increase. Quarter-end value: ~$14.86 billion, ranked fifth, and one of the top five buys of the quarter.
Microsoft holdings grew 2.96% to ~$17.65 billion, holding steady at third.
Apple slipped to second but shed only 0.24% of its shares, valued at ~$19.90 billion — less an active trim than a relative-ranking shift caused by AstraZeneca's surge.
This means → all three mega-cap tech names saw net additions; Nvidia's was the most aggressive. Apple "losing the top spot" is a ranking story, not a conviction story.
What do the ETF and options positions signal?
Fourth-largest holding S&P 500 ETF (IVV) dipped 0.72% in share count. Positions six through ten: S&P Total Market ETF (ITOT), Alphabet, MSCI EAFE ETF (IEFA), S&P 500 ETF (SPY), and Broadcom.
The options book is more telling: Nasdaq-100 ETF call options declared at ~$6.06 billion, Russell 2000 ETF put options at ~$5.77 billion — both saw significant weight increases and both ranked among the top five buys.
In plain terms = buying large-cap tech calls for upside while buying small-cap puts for protection — a classic "bullish big-cap, hedge small-cap" combo.
What was trimmed or exited?
Top five sells: Visa, S&P 500 ETF put options, SanDisk, Vanguard Mid-Cap ETF, and iShares Russell Mid-Cap ETF.
Vanguard Mid-Cap ETF saw the steepest cut at 10.45% — the largest trim among the top 20 holdings.
The fund opened 551 new positions (mostly options; the largest was Moderna call options at ~$462 million) and exited 514 — high activity on both sides, with an overall turnover rate of 13.94%.
What does the overall portfolio picture tell us?
Quarter-end total market value: ~$640 billion, up ~3.23% from last quarter — but much of that ~$20 billion increase reflects price appreciation in existing holdings, not equivalent net inflows.
Top-ten concentration sits at 22.12% — not especially high, indicating a still-diversified book.
This reflects a Q3 playbook of "add pharma (AstraZeneca), add chips (Nvidia), trim mid-and-small-caps, and use options for directional hedging." The key variables for the next 13F: whether AstraZeneca's weight surge persists, and whether the Nvidia build extends further in Q4.
市场有风险,内容仅供研究参考,不构成投资建议。
